Parkinson's Disease

Parkinson's disease is a brain disorder. It occurs when certain nerve cells (neurons) in a part of the brain called the substantia nigra die or become impaired. When approximately 80 percent of neurons are damaged, the symptoms of Parkinson's disease appear. Parkinson's disease affects 1 in 100 people over the age of 60, with the average age of onset being 60 years. The risk of developing Parkinson's disease increases with age. In the United States, it is estimated that 60,000 new cases of Parkinson's disease are diagnosed each year, with 1.5 million Americans currently living with the disease.

Overview

Feature Articles

Latest Parkinson's Disease News and Research

Blood test offers insight into Alzheimer's stage and severity

Blood test offers insight into Alzheimer's stage and severity

Novel PET imaging method quantifies brain inflammation enzyme

Novel PET imaging method quantifies brain inflammation enzyme

Scientists confirm neurobiochemical link between dopamine and cognitive flexibility

Scientists confirm neurobiochemical link between dopamine and cognitive flexibility

New light-driven process could accelerate the discovery of new drugs

New light-driven process could accelerate the discovery of new drugs

Targeting brain’s waste removal system may help combat cognitive decline

Targeting brain’s waste removal system may help combat cognitive decline

Groundbreaking stem cell therapy trial for Alzheimer's disease underway at UTHealth Houston

Groundbreaking stem cell therapy trial for Alzheimer's disease underway at UTHealth Houston

WEHI team makes major strides in the fight against Parkinson's disease

WEHI team makes major strides in the fight against Parkinson's disease

Portable system detects mild cognitive impairment in older adults

Portable system detects mild cognitive impairment in older adults

Compound found in rosemary shows promise for Alzheimer's treatment

Compound found in rosemary shows promise for Alzheimer's treatment

Can microbiome discoveries finally become treatments? Scientists show the way

Can microbiome discoveries finally become treatments? Scientists show the way

Study links ITSN1 gene variants to increased Parkinson's disease risk

Study links ITSN1 gene variants to increased Parkinson's disease risk

Phase 1 trial examines safety and feasibility of stem cell treatment for Parkinson's

Phase 1 trial examines safety and feasibility of stem cell treatment for Parkinson's

Projections show Parkinson's disease cases will reach 25.2 million by 2050

Projections show Parkinson's disease cases will reach 25.2 million by 2050

Exploring the role of subventricular zone in neural regeneration, neurodegenerative diseases

Exploring the role of subventricular zone in neural regeneration, neurodegenerative diseases

Non-invasive 40Hz gamma stimulation could help fight Alzheimer’s

Non-invasive 40Hz gamma stimulation could help fight Alzheimer’s

Medtronic receives FDA approval for BrainSense Adaptive DBS technology

Medtronic receives FDA approval for BrainSense Adaptive DBS technology

Early CPAP treatment may reduce Parkinson's disease risk in people with sleep apnea

Early CPAP treatment may reduce Parkinson's disease risk in people with sleep apnea

TFE3 activation shows promise for counteracting Parkinson's disease pathology

TFE3 activation shows promise for counteracting Parkinson's disease pathology

Study reveals how air pollution contributes to Alzheimer's disease

Study reveals how air pollution contributes to Alzheimer's disease

LJI scientists discover a potential new target for treating Parkinson's disease

LJI scientists discover a potential new target for treating Parkinson's disease

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.